Fig. 1

1–10 Clinical course of R14-induced relapsing EAU in rats after intravitreal injection of PP-001. Both rat eyes were injected once intravitreally with 6 μl PBS or 3 μg PP-001/6 μl PBS at day 18 (dashed line, resolution of primary inflammation) post immunization with R14-CFA. The clinical course is shown for each eye from each rat of both groups. The dotted line at day 24 defines the time period of therapeutic activity of intraocular PP-001. Relapses were defined as a clinical score of > 0.5 following a score ≦ 0.5. * Indicate relapses between days 19 and 24, + the relapses from day 25 until the end of the experiment. The gray areas show the negative/low inflammation scores that have to be exceeded for the definition of a relapse. Triangles: right eyes, black dots: left eyes. The right eye of rat PP-001/no. 7 was perforated during the injection and thus omitted from further evaluation. N = 10 rats per group; PBS n = 20 eyes, PP-001 n = 19 eyes after injection. Representative data are shown from experiment 1 of two independent experiments